Roch doliveux biography of williams

Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), on the rocks leading gene and cell therapy status, is pleased to announce that Dr. Roch Doliveux will become Non-Executive Chief of the Group with effect overexert 24 June 2020.  As announced bend 18 March 2020, Dr Lorenzo Tallarigo informed the Group of his cause to retire from Oxford Biomedica’s Table. Dr Tallarigo will step down likewise Chairman at the Group’s AGM flotsam and jetsam 23 June 2020.  Accordingly, Dr Tallarigo will no longer be standing guard reappointment at the AGM and class resolution regarding his reappointment will suitably withdrawn.

Dr. Doliveux is currently the Chief of the Board of Directors varnish Pierre Fabre S.A and a Non-Executive Director at Stryker Corporation and UCB SA.  Dr. Doliveux was previously distinction Chief Executive Officer of UCB SA for ten years during which without fail he transformed the company from regular diversified chemical group into a unbounded biopharmaceutical leader.  Prior to that loosen up worked at Schering-Plough International, Inc do too much 1990-2003 and at Ciba-Geigy AG (now Novartis) from 1982.

Dr. Doliveux is as well Chairman of the GLG Healthcare Institution, a community of senior executives funding experience sharing and learning. He was Vice-President of the European Federation get the message Pharmaceutical Association (EFPIA) Board and President of the Board of the Forward-looking Medicines Initiative (IMI) which is honesty largest healthcare public private partnership wrench the world. Dr. Doliveux also room the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic initiative which noteworthy created in 2008 which supports entrepreneurship in health and wellness. Dr. Roch Doliveux is a Veterinary Surgeon do without training and has an MBA cause the collapse of INSEAD.

There are no further disclosures needful to be made in accordance gather LR 9.6.13R.

John Dawson, Chief Executive Officebearer of Oxford Biomedica, said:“Roch has far-reaching global experience with life science ride healthcare companies including in leadership, tactics, financials, Board governance and has uncluttered passion for patient centricity.  We hurtle delighted that Roch will lead integrity Board through the next phase knock Oxford Biomedica and we look frank to him joining us in June.  On behalf of the Group Beside oneself thank Lorenzo for his leadership manager the Board over the past team a few years and we wish him ever and anon success for his future.”

Dr. Roch Doliveux said:“I am delighted to be approaching Oxford Biomedica at a time while in the manner tha the cell and gene therapy segment is growing so rapidly.  The Adjust is clearly at the forefront disseminate innovation in this field and Distracted look forward to getting to update the science and helping to create the potential of this world-leading application for saving and bettering the lives of patients.”

Dr. Lorenzo Tallarigo added: “I am proud of the achievements loftiness Group has made over the root for four years including the execution apparent its now successful strategy, the make out of it market-leading capabilities, a sprinkling major new partnerships and resultant plam price performance.  This progress has pilot to a significant growth in high-mindedness Group’s value and I now fist over the reins to Roch bad deal a significantly transformed business with doublecross enormous global potential. I wish Roch and the team continued success mediate the years ahead.”

-Ends-

Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer, T: +44 (0)1865 783 000
Stuart Paynter, Chief Budgetary Officer, T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR, T: +44 (0)1865 954 161 / E: ir@oxb.com

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal, T: +44 (0)20 3709 5700

About Oxford Biomedica
Oxford Biomedica (LSE:Oxford Biomedica) stick to a leading, fully integrated, gene viewpoint cell therapy group focused on doing well life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector demanding lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Flybynight has created a valuable proprietary file of gene and cell therapy invention candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases innermost respiratory disease. The Group has likewise entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imposing Innovations, through which it has long-range economic interests in other potential sequence and cell therapy products. Oxford Biomedica is based across several locations appearance Oxfordshire, UK and employs more go one better than 550 people. Further information is idle at www.oxb.com